Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling

Although epidermal growth factor receptor (EGFR)-targeted therapy has improved clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) carrying activating EGFR mutations, the development of acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), including the promi...

Full description

Saved in:
Bibliographic Details
Published in:Lung Cancer (Auckl)
Main Authors: Yu, Danlei, Zhao, Wen, Vallega, Karin A, Sun, Shi-Yong
Format: Artigo
Language:Inglês
Published: Dove 2021
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7872905/
https://ncbi.nlm.nih.gov/pubmed/33574724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S293902
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items